



ASX Announcement and Media Release

SciGen's Insulin registered in Thailand

Singapore & Australia. 14 November 2005. Biopharmaceutical company SciGen Limited (ASX: SIE) ("SciGen" or the "Company") is pleased to announce it has received the license to market its Insulin product SciLin™ in the Kingdom of Thailand.

According to World Health Organization, more than 3.5 Million Thais are diagnosed with diabetes with a large number of the population remaining undiagnosed.

The insulin pharmaceutical market in Thailand is estimated to be US\$15 Million. This market is presently shared by two multi-national companies.

Preparations are under way for the launch of SciLin in Thailand to occur early next year.

SciLin™ is a recombinant human Insulin developed together with its R & D partner Biotechnology General IL Ltd and with the exclusive license to manufacture and market in the Asia Pacific Region.

"We are delighted with yet another regulatory approval for SciLin™. This provides SciGen with an expanded market for the product. We shall continue to aggressively pursue regulatory approval in the rest of the Asia Pacific region," said Saul Mashaal, CEO of SciGen.

SciLin™ is currently registered and sold by SciGen or its partners in India, Vietnam, Pakistan and soon to be launched in the Philippines.

About SciGen

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices in Australia, USA, Korea, Vietnam, Hong Kong, and Philippines and partners in India, China, Indonesia, Israel, Poland, Austria and the Netherlands.

Further information:

Investor Relations and Media	Company
Rebecca Wilson Buchan Consulting +61 2 9237 2800 +61 417 382 391 (mobile) rwilson@bcg.com.au	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)